Glenmark Pharma has received a warning letter from the US Food and Drug Administration (USFDA) regarding its Indore manufacturing plant. The inspection happened between 3 February and 14 February 2025.
The company made it clear that this warning won’t affect its supply chain or hit revenues. It said that operations at the Indore unit will go on as usual.
In a firm statement, Glenmark Pharma said it is taking all steps to fix the issues raised by the USFDA. It also confirmed that there were no concerns about data integrity during the inspection. This is important, as data integrity issues often lead to bigger regulatory problems.
Glenmark assured investors and the public that it is committed to high standards in all its facilities. It also promised to work closely with USFDA to resolve the matter quickly. The company added that it continues to follow Current Good Manufacturing Practices (CGMP).
This isn’t Glenmark’s first brush with regulators, but the company’s calm and quick response shows its confidence. The message is clear: the company is standing strong.
Also Read Glenmark Pharma Signs $700M Cancer Drug Licensing Deal with AbbVie
For those who don’t know, Glenmark Pharma is a global, research-led company. It makes branded drugs, generic medicines, and over-the-counter (OTC) products. Its key focus is in respiratory, skin-related (dermatology), and cancer (oncology) medicines.
On the financial front, Glenmark had a good Q4 in March 2025. The company reported a net profit of ₹4.65 crore, compared to a net loss of ₹1,218.28 crore in the same quarter last year. Its net sales went up by 6.77%, reaching ₹3,220.13 crore.
However, the market reacted mildly. The stock price of Glenmark Pharma slipped by 0.56%, closing at ₹2,169.30 on the BSE. It seems investors are watching closely, but not panicking.
The warning may sound serious, but Glenmark’s steady tone and clear action plan show confidence. It’s facing the issue head-on. With no red flags on data integrity and no hit to revenues, the company looks ready to bounce back.
In short, Glenmark Pharma isn’t shaken. It’s treating the USFDA warning not as a threat, but as a checklist — and it plans to tick all the boxes fast.
Also Read Glenmark Launches TEVIMBRA in India for Lung, Esophageal Cancer Treatment
